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Objective. We sought to investigate whether the peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand pioglitazone can
attenuate vascular ﬁbrosis in spontaneously hypertensive rats (SHRs) and explore the possible molecular mechanisms. Methods.
SHRs (8-week-old males) were randomly divided into 3 groups (n = 8 each) for treatment: pioglitazone (10mg/kg/day),
hydralazine (25mg/kg/day), or saline. Normal male Wistar Kyoto (WKY) rats (n = 8) served as normal controls. Twelve weeks
later, we evaluated the eﬀect of pioglitazone on vascular ﬁbrosis by Masson’s trichrome and immunohistochemical staining of
collagen III and real-time RT-PCR analysis of collagen I, III and ﬁbronectin mRNA.Vascular expression of PPAR-γ and connective
tissue growth factor (CTGF) and transforming growth factor-β (TGF-β) expression were evaluated by immunohistochemical
staining, western blot analysis, and real-time RT-PCR. Results. Pioglitazone and hydralazine treatment signiﬁcantly decreased
systolic blood pressure in SHRs. Masson’s trichrome staining for collagen III and real-time RT-PCR analysis of collagen I, III and
ﬁbronectin mRNA indicated that pioglitazone signiﬁcantly inhibited extracellular matrix production in the aorta. Compared with
Wistar Kyoto rats, SHRs showed signiﬁcantly increased vascular CTGF expression. Pioglitazone treatment signiﬁcantly increased
PPAR-γ expression and inhibited CTGF expression but had no eﬀect on TGF-β expression. Conclusions. The results indicate that
pioglitazone attenuated vascular ﬁbrosis in SHRs by inhibiting CTGF expression in a TGF-β-independent mechanism.
1.Introduction
Vascular ﬁbrosis, characterized by excessive deposition of
extracellular matrix (ECM) (e.g., collagen and ﬁbronectin),
is a major complication of hypertension and diabetes
[1]. Connective tissue growth factor (CTGF) is a potent
proﬁbrotic factor implicated in pathologic ﬁbrosis processes
[2, 3]. In the cardiovascular system, CTGF is overexpressed
inatheroscleroticlesions[4]andarteriesofhypertensiveani-
mals [5]. In vascular smooth muscle cells (VSMCs), CTGF is
involvedincellproliferation,migration,andapoptosis[6,7].
Moreover, angiotensin II (Ang II) increases the production
of CTGF and ECM, so CTGF is an intracellular mediator of
hypertension-induced vascular ﬁbrosis [8].
Thiazolidinediones (TZDs) such as pioglitazone are
high-aﬃnity ligands for peroxisome proliferator-activated
receptor γ (PPAR-γ), a transcription factor of the nuclease
hormone receptor superfamily [9]. TZDs are mainly used as
insulin-sensitizing drugs in type 2 diabetes mellitus. They
have potential roles in cardiovascular ﬁbrosis [10]. In vitro,
TZDs attenuate cardiovascular ﬁbrosis by preventing ECM
production and cell growth, thus inhibiting the inﬂamma-
toryresponseandapoptosisinﬁbroblasts[11].In vivo,TZ Ds
could prevent cardiovascular ﬁbrosis in rats with myocardial
infarction [12] and Ang-II-infused and deoxycorticosterone,
acetate-salt-treated rats [13, 14]. Whether TZDs could
attenuate hypertension-induced vascular ﬁbrosis and the
possible mechanism have never been explored.2 PPAR Research
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Figure 1: Systolic blood pressure in WKY and SHR rats after 12 weeks of treatment. WKY, Wistar Kyoto rats; SHR, spontaneously
hypertensive rats; PIO, SHRs treated with pioglitazone; HYZ, SHRs treated with hydralazine. Values are mean ± SD.
∗P < 0.05 versus
WKY; #P < 0.05 versus SHR.
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Figure 2: Masson’s trichrome staining for ﬁbrosis and immunohistochemical staining for collagen III and quantiﬁcation (n = 6 rats, each
group). Scale bar: 50 mm. Data are mean ± SD of 24 measurements in 6 slides.
∗P < 0.05 versus WKY; #P < 0.05 versus SHR.PPAR Research 3
WKY SHR PIO HYZ WKY SHR PIO HYZ
WKY SHR PIO HYZ
10
8
6
4
2
0
10
8
6
4
2
0
10
8
6
4
2
0
F
N
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
r
e
l
a
t
i
v
e
 
t
o
 
G
A
P
D
H
 
(
n
-
f
o
l
d
)
r
e
l
a
t
i
v
e
 
t
o
 
G
A
P
D
H
 
(
n
-
f
o
l
d
)
C
o
l
 
I
I
I
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
r
e
l
a
t
i
v
e
 
t
o
 
G
A
P
D
H
 
(
n
-
f
o
l
d
)
C
o
l
 
I
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
#
#
#
∗
∗
∗
Figure 3: Eﬀect of pioglitazone on collagen I, III and ﬁbronectin mRNA expression. Data are relative to GAPDH expression and are
mean ± SD of 3 experiments.
∗P < 0.05 versus WKY; #P < 0.05 versus SHR.
In this study, we observed the eﬀects of pioglitazone on
vascular ﬁbrosis, and the expression of transforming growth
factor β (TGF-β) and CTGF in spontaneously hypertensive
rats (SHRs) to ascertain whether administering pioglitazone
could attenuate vascular ﬁbrosis with hypertension and to
understand the underlying mechanisms.
2.MaterialsandMethods
Our study was approved by the Institutional Animal Care
CommitteeofXianJiaotongUniversityandwasconductedin
accordance with the US National Institutes of Health Guide
for the Care and Use of Laboratory Animals (Publication no.
85-23, revised 1996).
The experiments involved 8-week-old male SHRs and
age-matched male Wistar Kyoto rats (provided by the
Shanghai SLAC Laboratory Animal Technique Corp.).
2.1. Reagents. Pioglitazone was from Takeda Pharmaceuti-
cals (Japan). Polyclonalanti-rat CTGF and TGF-β antibodies
werefromSantaCruzBiotechnology(SantaCruz,CA,USA).
RabbitpolyclonalantibodyagainstPPAR-γ wasfromUpstate
Inc. (Chicago, IL, USA). DAB Horseradish Peroxidase Color
Development Kit was from Beyotime (Suzhou, China),
TRIzol and SuperScript III Platinum SYBR-Green Two-Step
qRT-PCR kits were from Invitrogen (Carlsbad, CA, USA).
DNA-free kit was from Ambion (Austin, TX, USA). Agarose
gels were from Spanish Biochemicals (Pronadisa, Madrid).
Reagents for enhanced chemiluminescence were from Pierce
Corp. (Rockford, IL, USA).
2.2. Protocol. Normal WKY rats were the normal control
group (n = 8). SHRs were randomly divided into 3 groups
(n = 8 each) for treatment by oral gavage for 12 weeks:
pioglitazone, 10mg/kg/day [15]; hydralazine, 25mg/kg/day;
saline control. All rats were housed under similar conditions
with a 12hr light/dark cycle at 21 ± 1◦C and humidity 55 ±
5%. Rats had free access to an ordinary diet and water.
Systolic blood pressure (SBP) was measured biweekly in
consciousratsbytail-cuﬀplethysmography.Bodyweightwas
recorded every week throughout the study period.
At 12 weeks, rats were killed by intra-aortic adminis-
tration of 10% potassium chloride and an excess amount
of pentobarbital. One portion of the aorta was dissected
and cleaned of fat and then frozen in liquid nitrogen for
RNA extraction, and another portion was ﬁxed in 4%
formaldehyde solution, embedded in paraﬃn, and cut into
sections, 4-5μm each, and, underwent trichromic Masson’s
trichrome and immunohistochemistry staining.
2.3. Real-Time RT-PCR. Total RNA was extracted by the
use of TRIzol reagent, and DNA was removed by the
use of the DNA-free kit. Real-time qRT-PCR with SYBR
involved the use of the SuperScript III Platinum Two-Step
qRT-PCR Kit on an ABI PRISM 7000 sequence detection
PCR system (Applied Biosystems, Foster City, CA, USA).4 PPAR Research
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Figure 4: Immunohistochemical staining and quantiﬁcation of peroxisome proliferator-activated receptor γ (PPAR-γ) in the thoracic aorta
ofrosiglitazone-treatedandrosiglitazone-untreatedratsafterangiotensinII(AngII)infusion(n = 6ratseach).Scalebar:50mm.
∗P < 0.05
versus WKY; #P < 0.05 versus SHR.
Theprimersusedwerepreviouslyreported[16].Resultswere
relative to the expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and were calculated by the 2−CT
method [17, 18].
2.4. Western Blot Analysis. Protein samples (20μg) were
resolved on 10% SDS-PAGE, transferred to polyvinylidene
diﬂuoride membranes in a semidry system (Bio-Rad, Her-
cules, CA), and incubated with antibodies against CTGF
(1:500), TGF-β (1:500), and β-actin (1:2000). Signals were
revealed by chemiluminescence and visualized by exposure
to X-ray ﬁlms. Optical density was quantiﬁed with use of the
Gel Doc 2000 system (Bio-Rad).
2.5. Immunohistochemistry. Paraﬃn-embedded rat thoracic
aorta sections were incubated with primary antibodies
against PPAR-γ (1:300) and collagen type III (Col III)
(1:250) overnight at 4◦C and then biotinylated and aﬃnity-
puriﬁed IgG (Zymed, USA) secondary antibody for 1hr
at 37◦C. A streptavidin-enzyme conjugate was sequentially
addedfor20min,andsampleswereincubatedwithsubstrate
3 ,3 -diaminobenzidine (DAB), and then they underwent
haematoxylin counterstaining. Negative control had no
primary antibody. Quantitative analyses were using Qwin
550 quantitative image analysis system (Leica, German) by
measuring the gray scale.
2.6. Statistical Analysis. Results are expressed as mean ±
SD. Statistical signiﬁcance between groups was assessed by
one-way ANOVA, followed by post hoc Duncan multiple
comparisons, with the use of SPSS v13.0 (SPSS Inc., Chicago,
IL). A P<0.05 was considered statistically signiﬁcant.
3. Results
3.1. SBP in Rats. At baseline and after treatment, SBP was
higher in the SHR treatment group than in WKY rats (P<
0.05) (Figure 1). After treatment, SBP was signiﬁcantly lower
withpioglitazoneandhydralazinetreatmentthanintheSHR
alone group (P<0.05); the groups did not diﬀer in body
weight or heart rate at baseline or after treatment (data not
shown).
3.2. Pioglitazone Attenuated ECM Expression in Thoracic
Aorta. We then evaluated whether pioglitazone attenuated
vascular ﬁbrosis in SHRs. SHRs showed signiﬁcant ECM
deposition in thoracic aortas on Masson’s trichrome and
immunohistochemical staining of Col III (Figure 2). Real-
time RT-PCR revealed increased ﬁbronectin (FN), collagen
I (Col I), and Col III mRNA expression in the aortic tissue
of SHRs, which was signiﬁcantly inhibited by pioglitazone
treatment (Figure 3). These results indicated that pioglita-
zone but not hydralazine attenuated ECM deposition as
compared with SHRs alone.
3.3. Vascular PPAR-γ Expression in Thoracic Aorta. Piogli-
tazone treatment increased PPAR-γ protein expression as
seen on immunohistochemistry (Figure 4) and was mainly
located in nuclei of VSMCs, which indicates that PPAR-γ
activationbypioglitazonemaybeinvolvedinthesuppression
of ECM expression in vivo. Hydralazine had little eﬀect on
PPAR-γ expression.
3.4. Eﬀect of Pioglitazone on CTGF and TGF-β Expression in
Thoracic Aorta. Real-time RT-PCR revealed increased CTGFPPAR Research 5
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Figure 5: Eﬀect of pioglitazone on mRNA and protein level of connective tissue growth factor (CTGF) and transforming growth factor β
(TGF-β) in rat aortas (a) Western blot analysis of protein level of CTGF and TGF-β. β-actin was an endogenous control.
∗P < 0.05 versus
WKY; #P < 0.05 versus SHR (b) Real-time RT-PCR analysis of mRNA level of CTGF and TGF-β. Data are relative to GAPDH expression
and are mean ± SD of 3 experiments.
∗P < 0.05 versus WKY; #P < 0.05 versus SHR.
mRNAexpressionintheaortictissueofSHRs,whichwassig-
niﬁcantly inhibited by pioglitazone treatment. Pioglitazone
also attenuated CTGF protein expression (Figure 5(a))b u t
had no eﬀect on TGF-β mRNA or protein expression in rat
thoracic aortas (Figure 5(b)).
4. Discussion
Hypertension causes structural changes in the arteries (vas-
cular remodeling) that involve alterations in cell growth,
VSMChypertrophy,andaccumulationofECM[19,20].Our
data demonstrate that the PPAR-γ ligand pioglitazone can
attenuate ECM production in the SHR aorta. Importantly,
these eﬀects are mediated in part by PPAR-γ activation likely
through a TGF-β-independent pathway to inhibit CTGF
expression. These ﬁndings provide novel evidence for the
beneﬁcial vascular eﬀect of pioglitazone.
We previously showed that another PPAR-γ ligand,
rosiglitazone, inhibited vascular ﬁbrosis in Ang-II-infused
rats [16]. In this study, we used SHRs, a typical rat
model of hypertension, as a hypertension and vascular ﬁ-
brosis model [10]. As expected, we found hypertension and
vascular ﬁbrosis in SHRs. Both pioglitazone and hydralazine
treatment signiﬁcantly lowered SBP, but only pioglitazone
attenuated ECM production in the rat aorta. Pioglitazone6 PPAR Research
has antihypertensive eﬀects on other hypertensive mod-
els and hypertensive patients [21–24]. The novel ﬁnding
that this agent reduced vascular ﬁbrosis in SHRs may be
explained by a direct action of pioglitazone on the vessel
wall. BP lowering does not appear to play a role, because
hydralazine decreased BP without any eﬀect on vascular
ﬁbrosis and CTGF or TGF-β expression. These in vivo
data conﬁrm and extend results from our previous in vitro
studies in which PPAR-γ ligands were shown to down-
regulate angiotensin-induced ECM production in VSMCs
[16].
CTGF has been postulated to be involved in conditions
involving overgrowth of connective tissue cells (e.g., sys-
temic sclerosis, cancer, ﬁbrotic conditions, and atheroscle-
rosis). Our previous study conﬁrmed that PPAR-γ ligand
inhibited CTGF overexpression in response to Ang II in
cultured VSMCs [16]. In the present study, treatment with
pioglitazone for 12 weeks in SHRs signiﬁcantly reduced
vascular CTGF expression and markedly alleviated ﬁbro-
sis inﬁltration. Thus, inhibiting vascular CTGF expression
to inhibit vascular ﬁbrosis may be a mechanism of the
beneﬁcial eﬀects of pioglitazone on vascular ﬁbrosis in
SHRs.
In vascular ﬁbrosis, TGF-β participates in regulating
CTGF and ECM production [25]; importantly, the CTGF
promoter has a TGF-β binding element [26], so we tested
whether reduction of CTGF by pioglitazone was due to
downregulated TGF-β expression. TGF-β expression in SHR
aortas was not aﬀected by pioglitazone, so pioglitazone
attenuatedCTGFexpressionbyaTGF-β-independentmech-
anism. Some recent studies support our results. Pioglitazone
attenuatedleftventricularhypertrophyandCTGFexpression
without aﬀecting TGF-β expression in stroke prone SHR
[27]. Ang II may induce CTGF production [28]a n dv a s c u l a r
ﬁbrosis [29]b yaT G F - β-independent mechanism. More-
over, in human kidney ﬁbroblasts, pioglitazone inhibited
cell growth and reduced matrix production in a TGF-
β-independent way [30]. Therefore, PPAR-γ may aﬀect
TGF-β-independent or post-TGF-β signals in regulating
CTGF expression. Our previous studies indicated PPAR-γ
activation downregulated CTGF expression via interaction
with Smads and JNK pathways [16, 31]. Recently, Kim
et al. [32] showed that another PPAR-γ ligand, rosiglitazone,
inhibited CTGF and ECM production through the mTOR-
P70S6 kinase and 4EBP1 pathways in vascular smooth
musclecells.Sowethinkpioglitazone-modulatedCTGFmay
mainly through pathwayssuch asSmads, JNK, mTOR-P70S6
kinase, and 4EBP1.
In summary, the present study demonstrates that the
PPAR-γ ligand pioglitazone attenuated vascular ﬁbrosis in
SHRs with hypertension by inhibiting CTGF expression by
aT G F - β-independent way. These observations point to a
potential mechanism of pioglitazone in preventing vascular
ﬁbrosis.
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